Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS.

Ouali Alami N, Schurr C, Olde Heuvel F, Tang L, Li Q, Tasdogan A, Kimbara A, Nettekoven M, Ottaviani G, Raposo C, Röver S, Rogers-Evans M, Rothenhäusler B, Ullmer C, Fingerle J, Grether U, Knuesel I, Boeckers TM, Ludolph A, Wirth T, Roselli F, Baumann B.

EMBO J. 2018 Jun 6. pii: e98697. doi: 10.15252/embj.201798697. [Epub ahead of print]

2.

Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases.

Nettekoven M, Adam JM, Bendels S, Bissantz C, Fingerle J, Grether U, Grüner S, Guba W, Kimbara A, Ottaviani G, Püllmann B, Rogers-Evans M, Röver S, Rothenhäusler B, Schmitt S, Schuler F, Schulz-Gasch T, Ullmer C.

ChemMedChem. 2016 Jan 19;11(2):179-89. doi: 10.1002/cmdc.201500218. Epub 2015 Jul 21.

PMID:
26228928
3.

Total synthesis and stereochemistry revision of mannopeptimycin aglycone.

Fuse S, Koinuma H, Kimbara A, Izumikawa M, Mifune Y, He H, Shin-ya K, Takahashi T, Doi T.

J Am Chem Soc. 2014 Aug 27;136(34):12011-7. doi: 10.1021/ja505105t. Epub 2014 Aug 13.

PMID:
25078546
4.

Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.

Nettekoven M, Fingerle J, Grether U, Grüner S, Kimbara A, Püllmann B, Rogers-Evans M, Röver S, Schuler F, Schulz-Gasch T, Ullmer C.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1177-81. doi: 10.1016/j.bmcl.2013.01.044. Epub 2013 Jan 23.

PMID:
23380378

Supplemental Content

Loading ...
Support Center